FFPE RNA Purification Kits
For the rapid and efficient extraction and purification of RNA (including microRNA) from FFPE samples
For research use only and NOT intended for in vitro diagnostics.
CEIVDD marked diagnostic version available here
FFPE RNA Purification Kits
For the rapid and efficient extraction and purification of RNA (including microRNA) from FFPE samples
Register today to receive an exclusive 15% off* on your first order.
Features and Benefits
- Extract total RNA (including microRNA) from FFPE samples
- No phenol extraction step
- Includes DNase for optional on-column DNA removal
- Isolated RNA is of the highest quality and integrity
- Isolate a diversity of RNA species
- Purified RNA is suitable for a variety of downstream applications, including Small RNA Sequencing. Find out more information on Norgen's NGS services
- Purification is based on spin column chromatography that uses Norgen’s proprietary resin separation matrix
Norgen’s FFPE RNA Purification Kits provide a rapid method for the isolation and purification of total RNA (including microRNA) from formalin-fixed paraffin-embedded (FFPE) tissue samples in as little as 1 hour. Using formalin to fix tissues leads to crosslinking of the RNA and proteins, and the process of embedding the tissue samples can also lead to fragmentation of the RNA over time. Norgen’s FFPE RNA Purification Kits provide conditions that allow for the partial reversing of the formalin modifications, resulting in a high quality and yield of RNA. These kits are able to purify all sizes of RNA, from large mRNA and ribosomal RNA down to microRNA (miRNA) and small interfering RNA (siRNA), depending on the age of the FFPE tissue as fragmentation of the RNA is known to occur over time. The RNA is preferentially purified from other cellular components without the use of phenol or chloroform.
FFPE RNA Purification Kit (Spin Column)
Maximum loading volume of 650 μL per column, and a maximum binding capacity of 50 μg per column.
FFPE RNA Purification 96-Well Kit (High Throughput)
Purification is based on 96-well column chromatography using Norgen’s proprietary resin as the separation matrix. Purification can be performed using either a vacuum manifold or centrifugation. Maximum loading volume of 400 μL per well, and a maximum binding capacity of 50 μg per well.
Details
Supporting Data
Kit Specifications
|
|
Maximum Column Binding Capacity |
Up to 50 µg RNA
|
Maximum Loading Volume Per Spin Column |
650 µL
|
Size of RNA Purified |
All sizes, including small RNA (< 200 nt)
|
Time to Complete 10 Purifications |
1-4 hours*
|
Maximum Amount of Starting Material |
5 slices of < 20 µm thick paraffin slices
25 mg of unsectioned block |
Average Yield |
Variable due to age of paraffin blocks
~2-3 µg of Total RNA per 1 mg of fresh FFPE hamster kidney |
Storage Conditions and Product Stability
All solutions should be kept tightly sealed and stored at room temperature. The DNAse I and Proteinase K should be stored at -20°C upon arrival. This kit is stable for 1 year from the date of shipment.
Component | Cat. 25300 (50 preps) | Cat. 25400 (2 x 96 preps) |
---|---|---|
Digestion Buffer A | 25 mL | 2 x 25 mL |
Buffer RL | 30 mL | 2 x 30 mL |
Enzyme Incubation Buffer | 6 mL | 2 x 6 mL |
Wash Solution A | 38 mL | 2 x 38 mL |
Elution Solution A | 6 mL | 2 x 20 mL |
Proteinase K | 12 mg | 2 x 20 mg |
DNase I | 1 vial | 2 x 500μL |
Micro Spin Columns | 50 | - |
96-Well Incubation Plate | - | 2 |
96-Well Plate | - | 2 |
Adhesive Tape | - | 8 |
Collection Tubes | 50 | - |
96-Well Collection Plate | - | 2 |
Elution Tubes (1.7 mL) | 50 | - |
96-Well Elution Plate | - | 2 |
Product Insert | 1 | 1 |
Documentation
FAQs
Spin Column, High Throughput
Poor RNA recovery could be due to one or more of the following:
- Incomplete lysis of cells or tissue.
Ensure that the appropriate amount of Digestion Buffer A with Proteinase K was used. Increase the incubation time. - Column has become clogged.
Do not exceed the recommended amounts of starting materials. The amount of starting material may need to be decreased if the column shows clogging below the recommended levels. See FAQ related to “Clogged Columns/wells” below. - An alternative elution solution was used.
It is recommended that the Elution Solution A supplied with this kit be used for maximum RNA recovery. - Ethanol or Buffer RL was not added to the lysate.
Ensure that the appropriate amount of ethanol and Buffer RL are added to the lysate before binding to the column. - Ethanol was not added to the Wash Solution A.
Ensure that 90 mL of 96 - 100% ethanol is added to the supplied Wash Solution A prior to use. - Low RNA content in cells or tissues used.
Different tissues and cells have different RNA contents, and thus the expected yield of RNA will vary greatly from these different sources. Please check literature to determine the expected RNA content of your starting material.
Clogged columns/wells can result from one or a combination of the following factors:
- Insufficient solubilization of cells or tissues.
Ensure that the appropriate amount of Digestion Buffer A was used for the amount of cells or tissue. - Maximum number of cells or amount of tissue exceeds kit specifications.
Refer to specifications to determine if the amount of starting material falls within kit specifications. - Clarified lysate was not used for the binding step.
Ensure that after the lysis step the sample is centrifuged if a significant amount of debris is present, and that only the clarified lysate is used in subsequent steps. - Centrifuge temperature is too low.
Ensure that the centrifuge remains at room temperature throughout the procedure. Temperatures below 15°C may cause precipitates to form that can cause the columns to clog.
RNA can be degraded due to the following factors:
- FFPE sample is old.
The quality of RNA purified may drastically decrease in old samples. For best performance, freshly prepared samples are highly recommended. - RNase contamination.
RNases may be introduced during the use of the kit. Ensure proper procedures are followed when working with RNA. Please refer to “Working with RNA” at the beginning of this user guide. - Procedure not performed quickly enough.
In order to maintain the integrity of the RNA, it is important that the procedure be performed quickly. This is especially important for the Cell Lysate Preparation Step in the Animal Tissue protocol, since the RNA in animal tissues is not protected after harvesting until it is disrupted and homogenized. - Improper storage of the purified RNA.
For short term storage, RNA samples may be stored at –20°C for a few days. It is recommended that samples be stored at –70°C for longer term storage. - Prolonged incubation at 80°C.
In order to reverse formalin cross-links, an incubation at 80°C is required. Do not exceed 15 minutes of incubation at 80°C as this will increase RNA fragmentation. - Starting material may have a high RNase content.
For starting materials with high RNase content, it is recommended that β-mercaptoethanol be added to the Buffer RL.
If the RNA does not perform well in downstream applications, it may be due to one or more of the following:
- RNA was not washed 3 times with the provided Wash Solution A.
Traces of salt from the binding step may remain in the sample if the well is not washed 3 times with Wash Solution A. Salt may interfere with downstream applications, and thus must be washed from the well. - Ethanol carryover.
Ensure that the dry spin under the Well Wash procedure is performed, in order to remove traces of ethanol prior to elution. Ethanol is known to interfere with many downstream applications. - Formalin crosslink was not completely reversed.
Ensure sufficient incubation at 80°C is performed in Step 2b in the protocol. Do not exceed 15 minutes of incubation at 80°C as this will increase RNA fragmentation.
Citations
Title | A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy |
Citation | Journal of the american cancer society 2023. |
Authors | Nikhil T. Sebastian MD, Amy Webb PhD, Konstantin Shilo MD, Ryan Robb BS, Meng Xu-Welliver MD, PhD, Karl Haglund MD, PhD, Jeremy Brownstein MD, Gina M. DeNicola PhD, Changxian Shen PhD, Terence M. Williams MD, PhD |
Title | Involucrin Expression and Association with Ki-67 in Paraffin Embedded Tissue of Canine Skin Tumors: A Retrospective Study |
Citation | The Thai Journal of Veterinary Medicine 2016. |
Authors | Assawawongkasem, N., Suriyaphol, G., Srisuwatanasagul, S., Theerawattanasirikul, S., & Sailasuta, A |
Title | MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies |
Citation | Journal of Thoracic Oncology 2015. |
Authors | S Patnaik, R Mallick, E Kannisto, R sharma, B Wiam, S Yendamuri, SS Dhillon |
Title | Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice |
Citation | Oncology Reports 2015. |
Authors | Joana Márquez1 , Jorge Mena1 , Iera Hernandez-Unzueta1 , Aitor Benedicto1 , Eduardo Sanz2 , Beatriz Arteta1* and Elvira Ola |
Title | Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes |
Citation | PNAS 2015. |
Authors | Wang, Z., Deng, Z., Dahmane, N., Tsai, K., Wang, P., Williams, D. R., ... & Conejo-Garcia, J. R |
Title | LMP1-deficient Epstein-Barr virus mutant required T cells for lympgomagenesis |
Citation | The Journal of Clinical Investigation 2014. |
Authors | SD Ma, X Xu, J Plowshay, EA Ranheim, WJ Burlingham, JL Jensen, F Aslmakopoulos, W Tang, ML Gulley, E Cesarman, JE Gumperz, SC Kenney |
Title | Robust global microRNA expression profiling using next-generation sequencing technologies |
Citation | Laboratory Investigation 2014. |
Authors | S Tam, R de Borja, M Tsao, JD McPherson |
Title | Factors affecting the yield of microRNAs from laser microdissectates of formalin-fixed tissue sections |
Citation | BioMed Central 2012. |
Authors | Santosh Patnaik, Eric Kannisto, Sai Yendamuri |
Title | Overexpression of the Lung Cancer-Prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells |
Citation | PLoS One. 2011;6(7):e22379. Epub 2011 Jul 18. 2011. |
Authors | Santosh Kumar Patnaik, Eric Kannisto, Reema Mallick, Sai Yendamuri |